COMPANY
Leadership Team
COMPANY
Leadership
Team
Improving the quality of healthcare worldwide
Committed to providing high quality, reliable, cutting-edge tools for molecular diagnostic and personalized molecular medicine.
Improving the quality of healthcare worldwide
Committed to providing high quality, reliable, cutting-edge tools for molecular diagnostic and personalized molecular medicine.
JEFFREY EDWARD MILLER, PH.D.
FOUNDER, CHIEF SCIENTIFIC OFFICER, CHIEF EXECUTIVE OFFICER & CHAIRMAN
Dr. Miller is a scientist, inventor, entrepreneur focused on Improving Lives with Precision Diagnostics® – coupling drug trials and therapeutic treatment regimens with optimized clinically-actionable diagnostic methods in order to select the correct patients and then monitor and track their response throughout the course of their disease. He received his undergraduate degree in Biochemistry from UCLA and a combined Ph.D. in Biochemistry & Molecular Biology from UCSB.
Prior to starting Invivoscribe, Dr. Miller had more than twenty years of combined experience in protein biochemistry, cellular and molecular immunology, cardiac physiology, virology, and molecular biology, experience he had developed working in laboratories at the Medical School, Department of Chemistry, Molecular Biology Institute at UCLA, while earning his Ph.D. at UCSB, and as a postdoctoral scientist at Applied Molecular Evolution. He also spent several years at Quest Diagnostics Nichols Institute, setting up the molecular oncology laboratory and developing and launching PCR-based molecular assays for infectious disease and hematopathology.
Dr. Miller has a number of patents, peer-reviewed publications, and he has contributed to chapters in textbooks. He has been a member of the Association for Molecular Pathology for more than two decades, and is a member of ASH, EHA, and ASCO.
MEGHNA BHATNAGAR
CHIEF FINANCIAL OFFICER
Meghna Bhatnagar joined Invivoscribe in 2010 as Chief Financial Officer. In this role she is responsible for leading the Invivoscribe global finance organization, along with human resources and information technology.
Meghna Bhatnagar joined Invivoscribe in 2010 as Chief Financial Officer. In this role she is responsible for leading the Invivoscribe global finance organization, along with human resources and information technology.
Since her arrival, Ms. Bhatnagar has played an integral role in directing all aspects of company strategy, planning and operations.
Ms. Bhatnagar has over 20 years of experience building and leading finance and IT teams in global companies. Prior to joining IVS, she served as COO of Radiant Technologies, a technology company focused on providing business management solutions to small and medium sized companies where she was responsible for leadership and development of an entire project delivery team with full P&L responsibility. She played a key role in guiding overall strategy of the company and at the same time provided leadership for operational improvements.
Ms. Bhatnagar began her career in at Nunhems Seeds, a company of Bayer AG. During her tenure at Bayer she managed comprehensive portfolio of responsibilities in Finance and Information Technology both at regional and global levels.
Ms. Bhatnagar graduated from Kurukshetra University in India with bachelor’s degree in Accounting and earned a MBA from MDI, a premier business school in India.
ANDREIA DE ALBUQUERQUE, PH.D.
CHIEF COMMERCIAL OFFICER
Dr. Andreia de Albuquerque joined Invivoscribe in 2015 and currently serves as the Chief Commercial Officer. In this role, she is responsible for leading Invivoscribe’s global partnerships with Pharma and Biotech’s, focusing on companion diagnostics development, custom assay development, clinical trial testing, corporate partnerships and other strategic relationships.
Prior to joining Invivoscribe, Dr. de Albuquerque has held roles in precision molecular diagnostics, focusing on development, implementation and validation of PCR and NGS assays for diagnostic and research purposes. Her work has resulted in several peer-reviewed publications and participations in international conferences. During this time, she was also responsible for overseeing laboratory diagnostic teams and operations.
Her extensive expertise in precision diagnostics and understanding of assay development and clinical testing, paved the way into Business Development, where she focus on accelerating drug approvals, by building successful partnerships, providing technical expertise and working closely with biomarker leaders, sample operations, clinical science and regulatory to implement CDx, IVD and R&D assays in clinical trials.
Dr. de Albuquerque earned her degree in Biology from the University of Coimbra (Portugal) and a combined Ph.D. in Oncology and Molecular Biology from the University of Dresden (Germany).
DR. BRADLEY PATAY, M.D.
CHIEF MEDICAL OFFICER
Dr. Patay is dedicated to improving health by integrating genomic knowledge into medical care. He has authored numerous articles in this field, presented at multiple conferences and has been featured in Bloomberg Business Week.
Dr. Patay is dedicated to improving health by integrating genomic knowledge into medical care. He has authored numerous articles in this field, presented at multiple conferences and has been featured in Bloomberg Business Week. He has been head of the internal medicine section at Scripps Torrey Pines, worked as an Assistant Professor at STSI, and has been a founding member of the Board, and Vice President of the College of Genomic Medicine, which was established in 2010 to educate physicians and other health care professionals about genomic medicine.
His diverse clinical experience prior to joining Scripps Clinic in 2005 includes four years as an internist and pediatrician at Neighborhood Healthcare, a private, nonprofit community healthcare practice, and at Palomar Hospital. At these institutions, Brad cared for a wide range of patients, from neonates to the elderly, in both intensive care and the general wards. Through his service on several committees, he helped improve the health care institutions’ systems.
Dr. Patay has also been both a principle investigator and sub-investigator on studies that have integrated genomic and phenotypic data into models that help elucidate such topics as blood pressure, longevity and cancer. He also serves on a committee that helps select patients for genome sequencing to elucidate their unknown conditions.
He graduated with honors in economics and molecular cell biology from the University of California at Berkeley and he was elected to Phi Beta Kappa. After receiving his M.D. degree at UC San Diego in 1997, he completed a medical residency at Banner Health in Phoenix, Arizona and earned board certifications in Internal Medicine and Pediatrics.
TANIA OBRANOVICH, BSc (Hons) PhD LLB
CHIEF IP AND LEGAL STRATEGY OFFICER
Dr. Tania Obranovich has more than 25 years’ experience developing and managing global IP portfolios in the biotechnology sector, in particular in relation to molecular, cellular and genomic technologies as they relate to diagnostics and therapeutics.
She has acquired this experience both through private practice, having spent more than a decade as a partner in a top tier IP firm, and as legal counsel for a US based diagnostics company where she ran patent and trade mark prosecution and drafting, in addition to overseeing all legal, compliance and corporate governance matters. Tania has practiced throughout her career as both a lawyer and patent attorney. Prior to these roles she completed a PhD and post-doctoral fellowship in immunology. In addition to her legal practice, Tania has lectured extensively in patent law at The University of Melbourne and Monash University and also speaks widely in relation to IP issues. She was heavily involved with navigating the Australian and US legal and policy issues that arose as a result of the Myriad gene patent litigation in both these jurisdictions. Tania received a Federal Government appointment to the Professional Standards Board for Patent and TM Attorneys in 2012 and has held several other Board positions.
Tania has served as Chief IP and Legal Strategy Officer to Invivoscribe since 2019.
DR. MEINDERT NIEMEIJER, PH.D., M.Sc.
CHIEF INFORMATION OFFICER
Dr. Meindert Niemeijer joined Invivoscribe in 2021 as Chief Information Officer. In this role he is responsible for leading the global bioinformatics, software and information technology teams. He has a background in Medical Image Analysis and Machine Learning and has more than a decade of experience in the medical device industry creating software based medical devices.
Dr. Niemeijer came to IVS from Digital Diagnostics where he led the teams that designed, built, documented and put into production the first autonomous diagnostic Artificial Intelligence (AI), cleared by the FDA. He is an experienced technology leader and deep learning expert passionate about developing AI based medical devices. During his career, he has built a deep expertise in medical device (software) development processes and the way in which these interact with quality management and other regulatory requirements. He loves building and developing technology, processes and teams.
Dr. Niemeijer obtained a PhD. in Medical Image Analysis and Machine Learning from Utrecht University in the Netherlands. In addition to that he has an M.Sc. in Medical Computer Science, also from Utrecht University.
JASON GERHOLD
V.P., GLOBAL REGULATORY, QUALITY, AND CLINICAL AFFAIRS
Jason Gerhold joined Invivoscribe in 2012 and currently serves as V.P., Global Regulatory, Quality, and Clinical Affairs focusing on developing high quality diagnostics that meet both international pathology needs and support pharma partner’s drug development programs. He directly manages employees in the US, Japan, and China, and is responsible for worldwide compliance to relevant laws, regulations, and standards.
Mr. Gerhold has over 20 years of experience in the biotech industry with biologic therapeutics and diagnostics, including process development, regulatory, quality, and clinical roles. Mr. Gerhold has worked in small, medium and large companies; successfully registering IVD and CDx products in several international markets, developing, improving, and maintaining quality management systems while serving as the management representative to regulatory authorities, and leading clinical teams managing international registrational studies. He is known for building strong rapport with regulators and working well with research and pharma teams resulting in highly successful partnerships. He has completed trainings and/or accreditations for ISO 13485 Lead Auditor, Six Sigma Greenbelt, Clinical Trials Administration, Project Management, and CTD writing.
JORDAN THORNES
V.P., GLOBAL CLINICAL LABORATORY OPERATIONS
Jordan Thornes joined Invivoscribe in 2004 and currently serves as V.P., Global Clinical Laboratory Operations. In this role, he is responsible for leading Invivoscribe’s global network of clinical labs, the Laboratory for Personalized Molecular Medicine®, (LabPMM®).
There are currently four such LabPMM facilities which are strategically located globally in San Diego, USA; Hallbergmoos (Munich), Germany; Shanghai, China and Kawasaki (Tokyo), Japan. LabPMM aids patients and pharmaceutical companies worldwide with globally standardized and clinically-actionable diagnostic methods. LabPMM utilizes proprietary biomarkers to select the correct patients and monitor and track their critically important response throughout the course of their disease.
YING HUANG, PH.D.
V.P., PRODUCT DEVELOPMENT
Dr. Ying Huang joined Invivoscribe in 2010 and currently serves as V.P., Product Development. In this role, she is responsible for leading Invivoscribe’s product development activities to address unmet clinical needs in the fields of molecular diagnostic and precision medicine.
Dr. Huang has over 25 years of research and industry experience with a broad knowledge in technology and assay development. She is passionate about developing novel methods using cutting edge technologies to improve lives with precision diagnostics. She has successfully led development teams through entire product development life cycle, from feasibility to RUO, CLIA and IVD grade product launches and post market support under respective regulatory standards. Prior to Invivoscribe, Dr. Huang worked at Illumina, ACEA Biosciences, Nanogen and MD Anderson Cancer Center. In those roles, she developed a variety of techniques ranging from isolating CTC using microfluidic devices to detecting biowarfare agents using electronic microarray. Dr. Huang was the PI for research grants from DARPA and NIH. She is the co-author of more than 60 publications and meeting abstracts and is the co-inventor of 9 patents.
Dr. Huang received her Ph.D in Electrical Engineering from Bangor University, UK and B.E. in Electronic Engineering from Xidian University, China.
LEADERSHIP TEAM
Related Articles
Clonality and Measurable Residual Disease (MRD) Testing on the Illumina NextSeq Sequencers
Invivoscribe Marketing2024-06-21T12:55:12-07:00June 21st, 2024|2024 Publications, Featured Publications, Publications|
LEADERSHIP TEAM
Related Articles
Clonality and Measurable Residual Disease (MRD) Testing on the Illumina NextSeq Sequencers
Invivoscribe Marketing2024-06-21T12:55:12-07:00June 21st, 2024|2024 Publications, Featured Publications, Publications|
